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Ovarian cancer is the leading cause of death in women with gynecological malignancy
and improvements in current treatments are needed. As with many other solid cancers,
the ovarian tumor microenvironment is emerging as a key player in tumor progression
and a potential therapeutic target. The tumor microenvironment contains several non-
malignant cell types that are known to contribute to tumor progression and metastasis.
Included in this population of non-malignant cells are several different types of immune
cells, of which tumor-associated macrophages (TAMs) are the most abundant. An increas-
ing amount of evidence is emerging to suggest that TAMs display a unique activation
profile in ovarian tumors and are able to create an immunosuppressive microenvironment,
allowing tumors to evade immune detection and promoting tumor progression.Therefore,
an increased understanding of how these immune cells interact with tumor cells and the
microenvironment will greatly benefit the development of more effective immunothera-
pies to treat ovarian cancer. This review focuses on the role of TAMs in the ovarian tumor
microenvironment and how they promote tumor progression.
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INTRODUCTION
Epithelial ovarian cancer (EOC) represents the leading cause of
cancer mortality in women with gynecological malignancy (1).
The overall 5-year survival rate for EOC patients is approximately
40%,although in the majority of patients diagnosed with advanced
disease, the survival rate is significantly less (2, 3). Current stan-
dard treatment for EOC involves surgical debulking followed
by platinum-based chemotherapy. Although initial response to
chemotherapy is high, recurrence of chemoresistant disease is
common and is a major contributor to the poor prognosis of EOC.
While much effort has gone into uncovering the genetic dri-
vers responsible for EOC initiation and progression, the tumor
microenvironment is now increasingly recognized to play an
important role in EOC. The tumor microenvironment consists
of several different cell types that interact with tumor cells,
and with each other, to influence tumor initiation, growth, and
metastasis. Immune cells represent a major component of the
tumor microenvironment and allow tumor cells to evade immune
destruction.
Evidence suggests that ovarian tumors, like many solid tumors,
are immunogenic, containing tumor infiltrating lymphocytes that
indicate an interaction between tumor cells and the host’s immune
system. In a seminal paper published by Zhang et al., the pres-
ence of CD3+ infiltrating T cells in tumors was shown to sig-
nificantly increase long term survival in patients with advanced
ovarian cancer (4). Five-year overall survival rates were 38% in
patients that contained infiltrating T cells in their tumors com-
pared to<5% in patients that contained no T cells. Furthermore,
multivariate analysis showed that the presence of intratumoral
T cells was an independent prognostic factor. Since then, sev-
eral studies have confirmed the positive association between the
presence of tumor infiltrating T cells and patient survival (5–8).
The influence of intratumoral T cells on patient outcome indi-
cates the immune system may play an antitumor role in ovar-
ian cancer; however spontaneous regression of tumors through
immune destruction is rare. In addition to cytotoxic T cells
that display antitumor characteristics, ovarian tumors contain a
plethora of other immune cell types that create an immuno-
suppressive tumor microenvironment. These include regulatory
T cells (Tregs), dendritic cells, myeloid-derived suppressor cells,
and tumor-associated macrophages (TAMs). TAMs represent the
most abundant immune cell type in the ovarian tumor microen-
vironment and play several roles in promoting tumor progression.
While all of these cell types have been shown to play an important
role in ovarian cancer, some of which have been reviewed else-
where (9, 10), this review focuses on the characteristics of ovarian
TAMs and their role in ovarian cancer.
TUMOR-ASSOCIATED MACROPHAGES
Macrophages are phagocytic cells of the immune system that are
derived from circulating monocytic precursors, which extravasate
into tissues and differentiate in response to local signals. They rep-
resent a heterogeneous population of cells that can function to
stimulate the immune system or to suppress it. This heterogene-
ity has been simplified to group macrophages broadly as either
“classically activated” or “alternatively activated” (11). Classically
activated macrophages, also known as M1-polarized macrophages,
are activated by cytokines such as interferon-γ (IFNγ) and produce
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pro-inflammatory and immunostimulatory cytokines (e.g., IL-12
and IL-23), and are involved in Th1 responses to infection. In
contrast, alternatively activated, or M2-polarized macrophages,
are activated by Th2 cytokines (e.g., IL-4, IL-10, and IL-13) are
immunosuppressive, and are involved in scavenging cellular debris
and tissue repair. In general, TAMs are thought to more closely
resemble the M2-polarized phenotype (12). The function of TAMs
has been extensively studied in many cancer types and in addition
to playing an immunosuppressive role in the tumor microenvi-
ronment, TAMs have been shown to promote tumor invasion,
growth, angiogenesis, and metastasis (13, 14). Given the variety of
roles that TAMs play in tumor progression, it is not surprising that
their presence in many tumor types is often associated with poor
prognosis (15–17).
RECRUITMENT AND CHARACTERISTICS OF TAMs IN
OVARIAN CANCER
Tumor-associated macrophages represent the most abundant infil-
trating immune population in human ovarian tumors and ascites
(18). Ovarian tumors recruit circulating monocytes and induce
differentiation into TAMs via expression of factors such as CCL2,
also known as monocyte chemotactic protein-1 (MCP-1), and
macrophage colony stimulating factor-1 (M-CSF or CSF-1). CCL2
is overexpressed in ovarian tumor cells and cell lines, but not
in TAMs (19). Interestingly, expression of its receptor, CCR2 is
defective in TAMs derived from ovarian cancer patients (20).
This may reflect a mechanism by which ovarian tumors retain
recruited macrophages in the tumor microenvironment. CSF-1 is
a cytokine considered to induce differentiation of macrophages
to an M2 phenotype (12) and is overexpressed in human ovar-
ian cancers (21, 22). Expression of CSF-1 is higher in malignant
ovarian tumors compared to borderline and benign tumors (23).
Initial studies characterizing TAMs in ovarian cancer
demonstrate that TAMs most closely resemble M2-polarized
macrophages and express M2 markers such as CD163, CD204,
CD206 (Mannose Receptor), and IL-10 (23–26). Ovarian TAMs
also express the immunosuppressive chemokines CCL18, which is
found in high levels in ascites from ovarian cancer patients (27)
and CCL22 (28). More recently, genome-wide expression profiling
has been used to investigate the polarization of TAMs in patients
with high-grade serous ovarian cancer. The transcriptome of 17
human ovarian TAM samples was compared to non-polarized
(M0) macrophages and identified differential expression of 1275
genes. Further analysis of these genes revealed that ovarian TAMs
display a mixed-polarization phenotype. TAMs displayed upregu-
lated expression of typical M2 markers such as CD163 and IL-10,
while other M2 markers were downregulated. Similarly, some M1
markers were upregulated in ovarian TAMs, such as CD86 and
TNF. This mixed-polarization phenotype has also been described
in other tumor types (29–32), and suggests that TAMs most closely
resemble macrophages involved in developmental processes.
TAMs AND PROGNOSIS IN OVARIAN CANCER
Studies investigating the presence of TAMs in ovarian cancer
demonstrate a significant increase in the number of TAMs in
malignant ovarian tumors compared to benign and borderline
tumors (23, 33, 34). However, their presence as determined by
staining for the macrophage marker CD68 does not influence
patient outcome (33, 35–37). Expression of specific M2-associated
markers in ovarian cancer indicates that certain subsets of ovarian
cancer TAMs can indeed predict patient prognosis. In addition to
CD68+ cells, Lan et al. also analyzed 110 advanced stage ovar-
ian cancers for the M2 marker CD163 and demonstrated that
both progression free survival and overall survival were signifi-
cantly reduced in patients with high numbers of CD163+ cells
(37). Serum levels of CD163 have also been shown to predict
poor prognosis in patients with ovarian cancer (38). Similarly,
another M2-associated marker was associated with poor progno-
sis in ovarian cancer. While absolute densities of CD206+ cells
were not prognostic, a high CD206/CD68 ratio was strongly asso-
ciated with worse progression free survival, and there was also a
trend toward poorer overall survival (35). Recent studies examin-
ing markers of both M1 (HLA-DR, iNOS) and M2-polarization
(CD163, VEGF) in ovarian cancer patients have demonstrated
that an increased M1/M2 ratio was associated with improved
patient survival (39, 40). One study quantified the M1/M2 ratio
in the tumor and the stroma and found that only the M1/M2
ratio of overall tumor macrophages or macrophages present intra-
tumorally were prognostic, the M1/M2 ratio in tumor stroma
was not predictive of improved survival (39), indicating that
macrophages infiltrating tumor cells may play a more important
role in tumor progression. Finally, expression of B7-H4 on the sur-
face of ovarian TAMs, but not expression in ovarian tumor cells,
was associated with reduced survival and the number of B7-H4+
macrophages was significantly increased in advanced disease (41).
These studies demonstrate that while total numbers of CD68+
macrophages present in ovarian tumors do not influence patient
outcome, there is strong evidence for specific subsets of TAMs as
prognostic factors in ovarian cancer.
In addition to surface markers present on TAMs, cytokines that
are important in TAM function are also elevated in human ovar-
ian cancers and associated with reduced survival. IL-6, which is
present at high level in ovarian cancer ascites and associated with
the generation of TAMs (42), is associated poor prognosis and
chemoresistance (43–45). Similarly, IL-10, produced by TAMs, is
increased in ovarian cancer and correlated with higher tumor
grade and poor patient outcome (45–48). High levels of CSF-1
have also been shown to be a poor prognostic factor in ovarian
cancer, when expressed in the tumor epithelium (21). Expression
of specific markers of ovarian TAMs, as well as cytokines that are
important in TAM function and recruitment acting as prognostic
factors in human ovarian cancer provide strong support for the
function of TAMs in ovarian cancer progression.
INTERACTIONS BETWEEN TAMs AND OVARIAN TUMOR
CELLS
Ovarian cancer cells produce a variety of factors that influence
TAM function and vice versa. Co-culture experiments using ovar-
ian cancer cell lines and macrophages have revealed much about
the interactions between these two cell types. Ovarian cancer
cells have been shown to recruit and induce differentiation of
macrophages that have tumor-promoting functions. Figure 1
depicts some of the important interactions between TAMs and
ovarian cancer cells.
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FIGURE 1 | Ovarian cancer cells produce multiple factors to recruit
immunosuppressiveTAMs into the tumor, where they act to promote
tumor progression through multiple mechanisms.
Following co-culture with ovarian cancer cells, macrophages
develop a cell-surface phenotype similar to TAMs isolated from
human ovarian tumors and a significant increase in genes such
as CCL2, CCL22, TNFα, TGFβ1, and VEGF (49). In addition,
co-culture with cancer cells upregulated the M2-associated Man-
nose Receptor (CD206) and Scavenger Receptor-A (SR-A, CD204),
which was not seen when macrophages were co-cultured with nor-
mal ovarian surface epithelial cells (49). The induction of SR-A on
macrophages was dependent on the presence of TNFα. Expression
of macrophage migratory inhibitory factor (MIF) and extracel-
lular matrix metalloprotease inhibitory factor (EMMPRIN) by
ovarian cancer cells induces an increase of MMP secretion by
macrophages (50), supporting a role for TAMs in tumor cell inva-
sion and angiogenesis. Downregulation of MIF in ovarian cancer
cells led to a decrease in the production of cytokines important in
TAM recruitment such as CCL2 and CCL22 in vitro and an increase
in survival and decrease in ascites in vivo (51). Furthermore,
inhibition of MIF in ovarian tumor-bearing mice resulted in a
decrease in proliferation, an increase in tumor cell apoptosis, and
a decrease in the expression of angiogenic factors such as VEGF
by tumors. Importantly, there was also a significant decrease in
macrophage infiltration in the ascites, as well as a decrease in IL-6
and TNFα, and an increase in M1-associated IL-12 (51). Ovarian
cancer cell lines and tumor biopsies have been shown to express
elevated levels of IL-6, TNF, CXCL12, and its receptor CXCR4, and
expression of these is co-regulated (52, 53). Decreasing the levels
of all of these cytokines and chemokines in ovarian cancer cells was
achieved by knocking down CXCR4 (52). When injected into mice,
CXCR4 knock-down cells produced a decrease in tumor growth
and an increase in survival. A significant decrease in the num-
ber of macrophages in tumors was also seen. Similar results were
achieved when mice were treated with an anti-TNF antibody (52).
These studies demonstrate that ovarian tumor cells employ several
methods to recruit and induce TAMs to an immunosuppressive
phenotype in the tumor microenvironment.
Due to the association between increased levels of IL-6 in
ovarian cancer patients and the development of chemoresistance
(44), Dijkgraaf et al. investigated the effect of platinum-based
chemotherapy on the differentiation of macrophages in vitro.
Treatment of ovarian cancer cell lines with cisplatin or carboplatin
led to an increased ability of some cell lines to induce differentia-
tion of monocytes to an M2-like phenotype (54). The underlying
mechanism behind this was due to chemotherapy-induced activa-
tion of the NFκB pathway, which resulted in an increase in IL-6 and
prostaglandin E2 by cancer cells that promoted M2-polarization of
macrophages. These results indicate that therapeutically inhibiting
this effect, for example, by blocking the IL-6 receptor may increase
the antitumor effects of platinum-based chemotherapy.
Ovarian tumor cells are a heterogeneous population in which
Alvero et al. have identified two distinct subpopulations that have
different stemness, inflammatory, and cytokine profiles (55–57).
Interestingly, these two populations of cells were found to have
unique effects on the differentiation of macrophages (58). Mono-
cytes cultured in Type I EOC cell (CD44+/MyD88+, cancer stem
cells) conditioned media demonstrated increased levels of scav-
enger receptors and cytokines important in tissue repair such as
CCL5, whereas those cultures in Type II cell conditioned media
demonstrated increases in IL-10, IL-8, and G-CSF and are more
likely to play an immunosuppressive role in the tumor microenvi-
ronment (58). Nonetheless, both tumor cell populations differen-
tiated monocytes into macrophages with tumor supportive, rather
than antitumor properties, and these results add another level of
complexity to interactions between ovarian tumor cells and their
microenvironment.
Tumor-associated macrophages have been found to promote
the invasiveness of ovarian tumor cells through multiple mech-
anisms. Co-culture of macrophages with human ovarian cancer
cell lines increases the invasiveness of tumor cells through TNFα-
dependent activation of JNK and NFκB signaling pathways (50).
Inhibition of IKKβ, a major activator of NFκB signaling, in ovar-
ian TAMs prevented tumor cell invasion as well as decreased TAM
production of M2 immunosuppressive cytokines and increased
production of M1-associated IL-12 and NOS2 (59). Adoptive
transfer of IKKβ-targeted TAMs into ovarian tumor-bearing mice
www.frontiersin.org June 2014 | Volume 4 | Article 137 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Colvin Macrophages in ovarian cancer
resulted in a significant decrease in tumor burden and a switch
to an antitumor TAM profile (59). The ability for TAMs to
promote tumor cell invasion is also dependent on expression of
SR-A. SR-A−/− macrophages displayed a reduced ability to pro-
mote invasion of ovarian cancer cells in vitro and slowed tumor
progression in vivo (60). Importantly, this study also demon-
strated that targeting SR-A therapeutically with a small molecule
inhibitor can prevent tumor progression in vivo. Another study
also demonstrated the important role macrophages play in ovarian
tumor progression by chemically depleting macrophages in vivo
with clodronate, which dramatically decreased tumor dissemina-
tion and the development of ascites in mice injected intraperi-
toneally with ovarian cancer cells, potentially due to a decrease
in VEGF production (61). These studies demonstrate that TAMs
promote ovarian tumor progression by employing several different
strategies.
Tumor-associated macrophages foster an immunosuppressive
microenvironment to promote the survival of tumor cells. Mono-
cytes and macrophages derived from peripheral blood and ascites
of ovarian cancer patients were found to be increased in num-
ber and to display a less differentiated phenotype compared to
cells derived from healthy donors (62). They were also shown to
have impaired antitumor activity due to defective cytotoxicity and
phagocytic abilities. Another mechanism by which TAMs promote
immunosuppression is via secretion of CCL22, which mediates
Treg cell trafficking to the tumor (28). B7-H4,which is expressed on
the surface of ovarian TAMs, also contributes to immunosuppres-
sion in the tumor microenvironment. B7-H4 expression is induced
by IL-6 and IL-10 and selectively blocking B7-H4 in macrophages
significantly increased T-cell proliferation, whereas ectopic expres-
sion of B7-H4 in macrophages inhibited T-cell proliferation (63).
In addition, the mannose receptor (CD206), which is expressed
on TAMs, has been shown to contribute to the immunosuppres-
sive function of TAMs by binding tumor mucins such as CA125,
which increases the levels of IL-10 and decreases levels of the T-
cell chemo-attractant CCL3 (24). Treatment of ovarian TAMs with
IFNγ is able to reduce TAM secretion of CCL18 and VEGF and
switch TAMs from an immunosuppressive to an immunostim-
ulatory phenotype (64). Inducing an M1 phenotype in ovarian
TAMs, for example, via treatment with IFNγ or targeting B7-H4
may prove useful in encouraging immune destruction in patients
with ovarian cancer.
As has been demonstrated in other cancers, TAMs are begin-
ning to emerge as promoters of angiogenesis in ovarian cancer.
Co-culturing of TAMs with ovarian cancer cell lines led to an
increase in expression of the pro-angiogenic cytokine IL-8. The
conditioned media from these co-cultures significantly increased
the migration and tube formation of endothelial cells compared to
conditioned media from tumor cells or TAMs alone (65), indicat-
ing interactions between tumor cells and TAMs are important for
promoting angiogenesis rather than direct interactions between
TAMs and endothelial cells. TAMs also promote lymphangio-
genesis in ovarian cancer. An increased TAM density was found
to be significantly associated with an increased lymphatic vessel
density in ovarian cancer patients and TAMs were shown to pro-
mote lymphatic endothelial cell proliferation, migration, and tube
formation in vitro (66). Further studies are required to identify
the mechanisms employed by ovarian TAMs in inducing ovarian
tumor angiogenesis.
CONCLUDING REMARKS
Tumor-associated macrophages have been shown to play a key
role in creating an immunosuppressive tumor microenvironment,
as well as promote tumor growth, progression, metastasis, and
angiogenesis. The studies mentioned in this review highlight sev-
eral targets through which TAMs may be targeted therapeutically
such as CSF-1, IL-6, NFκB and suggest that depletion of TAMs, or
re-education to an immunostimulatory phenotype, may result in a
decrease in tumor growth and spread as well as enhance response
to chemotherapy. In ovarian cancer, much of the research into
TAMs has so far been limited to immunohistochemical charac-
terization in human patient samples and in vitro evaluation of
their effects on ovarian tumor cells. Compared to other tumor
types, a relatively limited number of in vivo studies have been
performed using xenograft and syngeneic mouse models. Results
from these models are potentially confounded by anti-tumorgraft
reactions present in syngeneic models and biased immune inter-
actions in xenograft models that use immunodeficient mice. The
best assessment of anti-TAM treatment strategies in ovarian cancer
would come from the use of spontaneous tumor models, however
there are few spontaneous ovarian cancer models available (67,68).
Additionally, whether the role of TAMs varies between each of the
histopathological subtypes has not been thoroughly investigated
and requires further study. Nonetheless, the work summarized
in this review demonstrate that TAMs represent an important
component of the ovarian tumor microenvironment, and fur-
ther studies will assist in evaluating this cell type as a potential
therapeutic target.
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